MELBOURNE Australia July 31, 2018: Imugene Limited (ASX:IMU), an immune-oncology Company is pleased to release its Appendix 4C for the quarter ended 30th June 2018.
Quarter highlights:
- Successfully raised $20.1 million (before costs), completed post quarter’s end;
- New cancer programs accelerate clinical development by 24 months;
- Established a clinical presence in the US with leaders in B-cell
therapeutics;
- HER-Vaxx trial recruitment continues with new trial sites in Europe.
The recent quarter was one of the most significant in the growth of our company.
For further information please download PDF attached:
Download this document
